We are hiring! If you are passionate about developing innovative new medicines with the potential to improve the lives of people with #cancer, check out our open roles. Our team is growing, and we have positions open in #CommercialOps, #MarketAccess, #MedicalAffairs, #TechOps and #IT. https://rb.gy/vftzqb #biotech #oncology
Nuvation Bio
Pharmaceutical Manufacturing
New York, NY 4,699 followers
Nuvation Bio is focused on treating the most difficult-to-treat cancers, for which conventional therapies have failed.
About us
Nuvation Bio is a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.
- Website
-
http://www.nuvationbio.com
External link for Nuvation Bio
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
1500 Broadway
STE: 1401
New York, NY 10036, US
-
585 Howard St.
3rd Floor
San Francisco, CA 94104, US
-
Shanghai, CN
Employees at Nuvation Bio
Updates
-
Qi Gong, Director, Biostatistics, enjoys working on statistics, programming and data management to further Nuvation’s mission to tackle some of the greatest unmet needs in #oncology. Exploring and resolving other functions’ needs through data science fulfils his knowledge and logical thinking strengths.
-
-
We enjoyed presenting our data, connecting with the #oncology community and celebrating exciting advances for people with #cancer at #ASCO24! Thanks to the Nuvation Bio team and our collaborators for their dedication and impact. Explore our updates: Press release: https://lnkd.in/eKaZ3dkg Oral presentation and Journal of Clinical Oncology publication: https://lnkd.in/e76cYDpG
-
-
#ASCO24 News: We are excited to announce data from the pivotal Phase 2 TRUST-I study of our investigational ROS1 inhibitor for #NSCLC are published in the American Society of Clinical Oncology (ASCO) Journal of Clinical Oncology. If you’re in Chicago, we hope to see you at the oral presentation today at 4:30 p.m. CT. Read more: https://lnkd.in/eKaZ3dkg #oncology #cancer
-
Next Wednesday, management will be presenting at the Jefferies Global Healthcare Conference. Tune in to hear about our pipeline of multiple clinical #oncology programs: https://lnkd.in/e3A8Sdcu
-
-
We are tremendously proud of David Hung, M.D., Nuvation Bio’s Founder, President, and CEO, for receiving the Ellis Island Medal of Honor last week! Among other distinguished figures, David was recognized by the Ellis Island Honors Society for his outstanding leadership in #oncology. David has developed new #cancer treatment innovations that have transformed patient care and saved lives, served on medical boards, and practiced as a physician. We feel so grateful for his visionary leadership at Nuvation Bio and could not think of anyone more deserving of this award, which celebrates patriotism, diversity, and immigrants’ contributions to our country’s economic and social success. Please join us in extending a well-deserved congratulations to David!
-
-
We are thrilled to be expanding our team of colleagues dedicated to improving the lives of people living with the most difficult-to-treat #cancers. Explore our culture, benefits and open roles in #IT, #MedicalAffairs, #TechOps and #CommercialOps at this exciting time for Nuvation Bio! https://lnkd.in/geQFgga #biotech #oncology
-
-
Today we reported first quarter 2024 financial results and provided a business update. See more: https://lnkd.in/eFifexXx #oncology #cancer #biotech
-
-
Happy #AdministrativeProfessionalsDay to Salina Ho and Jaclyn Gardner! You keep our offices running smoothly and are fun, collaborative contributors to our culture. Join us in saying thank you for all they do as we collectively tackle some of the greatest unmet needs in #oncology.
-
-
We look forward to #ASCO24! Today we announced an oral presentation on updated data from the Phase 2 study evaluating taletrectinib in patients with ROS1-positive #NSCLC. Learn more: https://lnkd.in/euGUfXqv #cancer #oncology
-